Drug Trial Radar · NCT04329650
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia
Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
163
Actual
Start
Apr 15, 2020
Primary completion
Feb 26, 2021
Study completion Feb 26, 2021
Sponsor
- Lead sponsor
- Judit Pich MartínezAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In our center up to 25% of the hospitalized patients with COVID-19 progress and need an intensive care unit. It is urgent to find measures that can avoid this progression to severe stages of the disease. We hypothesize that the use of anti-inflammatory drugs used at the time they start hyperinflammation episodes could improve symptoms and prognosis of patients and prevent their progression sufficiently to avoid their need for be admitted to an Intensive Care Unit.
Conditions
- COVID-19
Interventions
SiltuximabDrug
A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
DexamethasoneDrug
A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients requiring ICU admission at any time within the study period.Time frame: 29 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hospital Germans Trias i Pujol
Badalona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Universitari Mútua de Terrassa
Terrassa, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.